For instance, in preclinical cancer models, HDACi were shown to enhance the efficacy of immune checkpoint blockade using anti-PD1/PDL1 or anti-CTLA4, immunostimulant therapies such as anti-CD40 and anti-CD137, and adoptive T cell immunotherapy (30–34). Here, PDCD1 is linked to cancer.